GlassScriptPhysician profile
Scott Douglas
NPI 1932632270
$2,789.32
in general payments reported to CMS, 2019-2025
21 companies · $899 in 2025
The $899 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $104 · 2023: $592 · 2024: $1,194 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,685.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,249.46 | 2022-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $244.56 | 2023-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $201.07 | 2024-2025 | Tremfya, Stelara |
| Pfizer INC. | $166.53 | 2023-2025 | |
| Ardelyx, INC. | $145.06 | 2023-2025 | Ibsrela |
| Celgene Corporation | $122.62 | 2023-2024 | Zeposia |
| Lilly USA, LLC | $121.30 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $103.83 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.52 | 2024-2025 | Xifaxan, Plenvu |
| Ferring Pharmaceuticals INC. | $62.99 | 2024-2025 | Rebyota |
| Phathom Pharmaceuticals, INC. | $62.44 | 2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $43.40 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $40.65 | 2023-2024 | Ocaliva |
| Genzyme Corporation | $25.53 | 2023 | |
| Madrigal Pharmaceuticals | $23.88 | 2024 | Resmetirom |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $22.48 | 2025 | Vegzelma |
| Sandoz INC. | $18.17 | 2024 | Hyrimoz |
| Merck Sharp & Dohme LLC | $17.27 | 2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $16.80 | 2023 | |
| Micro-Tech Endoscopy USA, INC. | $16.04 | 2023 | Dat Closure Device |
| Aimmune Therapeutics, INC. | $15.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.